Methylphenidate: Difference between revisions

Line 1:

'''Methylphenidate''' (also known as '''MPH''', '''MPD''', and the trade names '''Ritalin''', '''Concerta''', and '''Methylin''', among others) is a classical potent ~~short-acting~~ [[psychoactive class::stimulant]] substance of the [[chemical class::phenidate]] class. It is the parent compound of the [[substituted phenidates]], a family of stimulants that includes [[ethylphenidate]], [[isopropylphenidate]], and others. The mechanism of action involves increasing concentrations of the [[neurotransmitters]] [[dopamine]] and [[norepinephrine]].

'''Methylphenidate''' (also known as '''MPH''', '''MPD''', and the trade names '''Ritalin''', '''Concerta''', and '''Methylin''', among others) is a classical potent[[psychoactive class::stimulant]] substance of the [[chemical class::phenidate]] class. It is the parent compound of the [[substituted phenidates]], a family of stimulants that includes [[ethylphenidate]], [[isopropylphenidate]], and others. The mechanism of action involves increasing concentrations of the [[neurotransmitters]] [[dopamine]] and [[norepinephrine]].

It was first synthesized in 1944 and was approved for medical use in the United States in 1955. It was originally sold by Swiss company CIBA (now Novartis).<ref>{{cite journal | vauthors=((Lange, K. W.)), ((Reichl, S.)), ((Lange, K. M.)), ((Tucha, L.)), ((Tucha, O.)) | journal=ADHD Attention Deficit and Hyperactivity Disorders | title=The history of attention deficit hyperactivity disorder | volume=2 | issue=4 | pages=241–255 | date= December 2010 | url=http://link.springer.com/10.1007/s12402-010-0045-8 | issn=1866-6116 | doi=10.1007/s12402-010-0045-8}}</ref> It is approved for treatment of attention-deficit hyperactivity disorder (ADHD) and narcolepsy. It is often used by students with or without ADHD as a cognitive enhancer and study aid.

@@ Line 1: / Line 1: @@
 {{SummarySheet}}
 {{SubstanceBox/Methylphenidate}}
-'''Methylphenidate''' (also known as '''MPH''', '''MPD''', and the trade names '''Ritalin''', '''Concerta''', and '''Methylin''', among others) is a classical potent short-acting [[psychoactive class::stimulant]] substance of the [[chemical class::phenidate]] class. It is the parent compound of the [[substituted phenidates]], a family of stimulants that includes [[ethylphenidate]], [[isopropylphenidate]], and others. The mechanism of action involves increasing concentrations of the [[neurotransmitters]] [[dopamine]] and [[norepinephrine]].
+'''Methylphenidate''' (also known as '''MPH''', '''MPD''', and the trade names '''Ritalin''', '''Concerta''', and '''Methylin''', among others) is a classical potent[[psychoactive class::stimulant]] substance of the [[chemical class::phenidate]] class. It is the parent compound of the [[substituted phenidates]], a family of stimulants that includes [[ethylphenidate]], [[isopropylphenidate]], and others. The mechanism of action involves increasing concentrations of the [[neurotransmitters]] [[dopamine]] and [[norepinephrine]].
 It was first synthesized in 1944 and was approved for medical use in the United States in 1955. It was originally sold by Swiss company CIBA (now Novartis).<ref>{{cite journal | vauthors=((Lange, K. W.)), ((Reichl, S.)), ((Lange, K. M.)), ((Tucha, L.)), ((Tucha, O.)) | journal=ADHD Attention Deficit and Hyperactivity Disorders | title=The history of attention deficit hyperactivity disorder | volume=2 | issue=4 | pages=241–255 | date= December 2010 | url=http://link.springer.com/10.1007/s12402-010-0045-8 | issn=1866-6116 | doi=10.1007/s12402-010-0045-8}}</ref> It is approved for treatment of attention-deficit hyperactivity disorder (ADHD) and narcolepsy. It is often used by students with or without ADHD as a cognitive enhancer and study aid.